Formulation method improves bioavailability of poorly soluble molecules

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/peterschreiber.media)
(Image: Getty/peterschreiber.media)

Related tags: Nanoform, formulation, bioavailability, Solubility

Orion to benefit from Nanoform’s formulation technology, which is able to improve bioavailability and solubility of early-stage compounds.

Finnish pharmaceutical company, Orion, has entered a partnership with nanoparticle formulation development company, Nanoform, aiming to improve the potential of new chemical entities and increase their likelihood of entering clinical development.

The partnership is based on Nanoform’s Controlled Expansion of Supercritical Solutions (CESS) formulation technology, able to produce nanoformed particles of active pharmaceutical ingredients (APIs) to specifications as small as 10nm.

CESS technology has the potential to enable poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability.

According to Nanoform, many new chemical entities struggle to progress into clinical development due to their physico-chemical properties, with the issue expected to exacerbate as molecular complexity increases in drug discovery.

However, ‘Nanoform-ed’ APIs have ‘shown promise’ for overcoming this challenge by increasing the powder dissolution and even intrinsic solubility of the compounds, the company stated, with the partnership expected to provide a path to clinical trials for poorly soluble molecules developed by Orion.

Juha Kiesvaara, VP of global pharmaceutical research at Orion, stated that utilizing nanoparticles could also result in a simplified formulation process.

According to Kiesvaara, Orion will benefit by Nanoform's technology enabling "[production] of tailored nanoparticles smaller than 200nm from solution, in a controlled and reproducible manner, with good yield and without the need for excipients," ​which is 'challenging' to do with currently available pharmaceutical manufacturing techniques.

Related news

Show more

Related products

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars